ホーム>>Signaling Pathways>> Ubiquitination/ Proteasome>> Autophagy>>FMK 9a

FMK 9a

カタログ番号GC36063

FMK 9a は、FRET および LRA アッセイで IC50 値が 80 および 73 μM のオートファジン 1 阻害剤です。

Products are for research use only. Not for human use. We do not sell to patients.

FMK 9a 化学構造

Cas No.: 1955550-51-2

サイズ 価格 在庫数 個数
10mM (in 1mL DMSO)
$280.00
在庫あり
1mg
$139.00
在庫あり
5mg
$324.00
在庫あり
10mg
$556.00
在庫あり
25mg
$1,112.00
在庫あり
50mg
$1,808.00
在庫あり
100mg
$3,152.00
在庫あり

Tel:(909) 407-4943 Email: sales@glpbio.com

顧客レビュー

カスタマーレビューに基づきます。

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

FMK 9a is an autophagin-1 inhibitor with IC50 values of 80 and 73 μM in FRET and LRA assay. IC50: 80 nM (autophagin-1, FRET assay); 73 nM (autophagin-1, LRA assay)[1]

ATG4B or autophagin-1 is a cysteine protease that cleaves ATG8 family proteins. ATG4B plays essential roles in the autophagosome formation and the autophagy pathway. FMK 9a shows strong inhibition of ATG4B, with IC50 values of 80 and 73 nM in the TR-FRET and cellular-based LRA assays, respectively. LC-MS/MS study indicates that FMK 9a forms an irreversible covalent bond with the more reactive thiol group of Cys74 located at the catalytic site of ATG4B and thus inactivates ATG4B proteolytic activity[1].

FMK 9a shows moderate solubility (LYSA: 41 μg/mL) and high human and mouse liver microsome clearances of 13.9 and 70 mL/kg per minute[1].

[1]. Qiu Z, et al. Discovery of Fluoromethylketone-Based Peptidomimetics as Covalent ATG4B (Autophagin-1) Inhibitors. ACS Med Chem Lett. 2016 Jun 25;7(8):802-6.

レビュー

Review for FMK 9a

Average Rating: 5 ★★★★★ (Based on Reviews and 19 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for FMK 9a

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.